Chris Armstrong
CEO | Direct Meds
What has been a significant challenge you’ve faced? How did you overcome it?
Building the plane while flying it. We’re working with relentless reprioritization, rapid iterations and leveraging years of professional networks to attract top-tier talent to tackle impossible challenges.
What are you most looking forward to accomplishing in 2026?
We’re looking forward to leveraging technology to build patient feedback loops to proactively monitor patient outcomes, reducing all unnecessary friction in the patient experience, diversifying our medication offering to existing patients, and further developing the team and systems required to 5x our revenue from 2025.
Describe the growth of your company in recent years. What other major achievements did the company accomplish under your leadership?
As a bootstrap startup, we launched in 2024 and Direct Meds created $8 million in revenue during our first year. In 2025, we grew to $80 million in revenue, with December of 2025 driving over $12 million in monthly revenue. Based on our patient needs, we were able to create a minimum viable product for our EMR three months after launch. We’ve acquired 125,000+ patients since launch and are now averaging over 1,000 new patients per day. We increased our staff from 15 to 115 employees in the same year. We acquired DNA supplement company Autumn (www.tryautumn.com). We acquired our first pharmacy in 2025. Our current revenue trajectory would put is on pace to do no less than $400 million in 2026, with an achievable goal of ending the year driving $80 million per month in revenue and growing.
